INTRODUCTION
*To whom correspondence should be addressed.
One of the current challenges of oncogenomics is to distinguish the genomic alterations that are involved in tumourigenesis (i.e., drivers), from those that give no advantage to cancer cells, but occur stochastically as a by-product of cancer development, (i.e., passengers). In line with this distinction, driver genes (i.e. those bearing driver alterations) confer selective advantage to tumour development and can be identified by detecting signals of positive selection across a cohort of tumours (Dees et al., 2012; Getz et al., 2007; Gonzalez-Perez & Lopez-Bigas, 2012; Greenman et al., 2007; Hodis et al., 2012; Reimand & Bader, 2013; Tamborero, Lopez-Bigas, & Gonzalez-Perez, 2013) . One of the most intuitive approaches -and the most profusely employed at present-to detect positive selection is based on frequency. Briefly, it consists in identifying genes more frequently mutated than the background mutation rate (Dees et al., 2012; Getz et al., 2007) . We recently described a second complementary approach, OncodriveFM (Gonzalez-Perez & Lopez-Bigas, 2012) , to identify genes under positive selection in tumour development by assessing their bias towards the accumulation of mutations with high functional impact (FMbias) across a cohort of tumour samples. Here we propose a third alternative and complementary approach aimed at detecting genes that bear mutations significantly clustered in specific regions of the amino acid sequence. Gain-of-function mutations in cancer genes predominantly occur at specific protein residues or active domains; for example, most KRAS mutations are found in residues 12 and 13 of the protein (Malumbres & Barbacid, 2003) , and mutations in PIK3CA are predominantly found in the kinase and helical domains of the PIK3CA subunit (Karakas, Bachman, & Park, 2006) . However, the extent of this phenomenon in cancer genes and how it can be used to nominate drivers, not just gain-of-function cancer genes, remains to be clarified.
The clustering of mutations in the amino acid sequence of proteins -mutations clustering, for clarity-has already been suggested as a marker of positive selection (Wagner, 2007) , and some approaches have been described to measure it in cancer (Stehr et al., 2011; Wagner, 2007; Ye, Pavlicek, Lunney, Rejto, & Teng, 2010; Yue et al., 2010) . However, the methods described in previous reports assume that mutation probability is homogeneous across the gene sequence, which is likely an oversimplification that introduces a bias in the detection of meaningful events. To solve this problem, we have developed OncodriveCLUST, a novel method that measures the bias of genes towards large mutation clustering with respect to a background model composed of coding-silent mutations, which are in principle under no selective pressure and thus may reflect the baseline clustering of somatic mutations. We have applied OncodriveCLUST to the set of mutations reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) (Forbes et al., 2010) , with the objective of assessing its performance to select known cancer drivers, i.e., those found in the Cancer Gene Census (CGC) (Futreal et al., 2004) , and to determine the extent of the mutations clustering phenomenon amongst known driver genes, both those described as oncogenes and tumour suppressors. We have also applied OncodriveCLUST to several available large datasets of cancer somatic mutations from The Cancer Genome Atlas (TCGA) initiative (Consortium et al., 2008) , and compared these results with other methods to identify driver candidates, namely OncodriveFM (Gonzalez-Perez & Lopez-Bigas, 2012) and MutSig (Getz et al., 2007) . Since all three approaches measure complementary and independent criteria aimed to discover positive selection (i.e., mutation clustering, FMbias and mutation frequency), and each of them likely detects important events, we conclude that the optimal solution is to combine them to retrieve the most reliable and comprehensive list of cancer drivers from datasets of somatic mutations of diverse tumour types.
METHODS

OncodriveCLUST implementation
The OncodriveCLUST method comprises the following five steps, illustrated in Figure 1 : First, single-nucleotide proteinaffecting mutations (i.e., non-synonymous, stop and splice site mutations) are retrieved (panel I). Second, positions with a number of mutations above a background rate threshold (those with a 1% or less probability of occurrence, according to the binomial cumulative distribution function which takes into account both the gene length and the overall number of gene mutation) are identified as potentially meaningful cluster seeds (panel II). Third, these positions are grouped to form clusters, joining positions that fall within distances of 5 or less amino-acid residues (panel III). Fourth, once these clusters are obtained, they are completed by including the positions within or adjacent to each cluster that contain mutations in addition to those considered in the second step (panel IV). Finally, a score is computed for each cluster. This score is directly proportional to the percentage of mutations grouped within the cluster and inversely proportional to its length, as shown in the equation, where i represents protein positions within the cluster, fractionMutations is the percentage of mutations falling in that position (out of the total observed in the protein across samples), and dist is the number of amino acids spanning between i and the position of the cluster with the largest number of mutations, i.e., its peak. Note that this score ranges between 0 and 1, where 1 means that a single position concentrates all the mutations observed in the gene across samples. The rationale behind considering the fraction of mutations instead of their absolute figure is to avoid overestimating the score of clusters in frequently mutated genes. On the other hand, inversely weighting the clustering score with the cluster length (see denominator) tends to favour genes with mutations concentrated in narrower regions (Supp Figure 1) . To complete the final step, a gene clustering score is obtained by summing the scores of all its clusters. Finally, the significance of the observed gene clustering score is estimated by comparing it with the background model distribution (panel V), obtained by calculating all gene clustering scores of the codingsilent mutations. Since the distribution of the null model is sufficiently close to normal, the significance is computed through a Z-score, which is then transformed into a p value and corrected for multiple testing using the False Discovery Rate approach. Therefore, this corrected p value measures the clustering bias of the protein-affecting mutations of a gene, compared to that of the coding-silent mutations measured across the data set.
OncodriveCLUST has been implemented as a Python script (downloadable from http://bg.upf.edu/oncodriveclust), which requires a file stating the position of each mutation within the protein sequence as input (see the user's guide for further details). The preparation of this file is at the user's discretion; note that the selection of the protein isoform may cause, among other factors, different consequence types of the mutations. In the present manuscript, we have processed the mutation data by using an in-house pipeline that selected the largest isoform. In addition, the launcher allows the use of several optional arguments in order to customize the values used by OncodriveCLUST internal calculations. Moreover, the user may also choose whether to output the details of the identified clusters and the protein domains to further explore the occurrence of mutations in known functional regions. Finally, the number of coding-silent mutations of the analysed data set must ensure the construction of a background model. For those cases in which this is not possible due to a reduced number of samples and/or a low occurrence of synonymous mutations, the method can be run with an 'external' background model computed from 26 datasets of different large cancer exome sequencing projects (see Supp Table I ) that are publicly available. However, the results of this analysis have to be carefully considered since it may be subjected to several inaccuracies due to technical (e.g. differences in mutation calling pipelines) and biological (e.g. differences in mutation clustering between tumors) considerations.
Application to the COSMIC dataset
Somatic mutations were downloaded from the COSMIC v.62 dataset (Forbes et al., 2010) and analysed by OncodriveCLUST including only those genes with at least 10 single-nucleotide protein-affecting mutations across all tumour samples in the dataset. Only entries labeled as genome-wide screen were selected in order to avoid the inclusion of mutations biased towards more intensively studied positions, which are overrepresented in COSMIC. In addition, and also to ensure a fair assessment of mutation clustering, we have also excluded mutations found in metastases, secondary and recurrent tumors, as well as mutations not explicitly declared as somatic, and mutations found in cell lines and xenografts. We obtained 233,775 protein-affecting mutations, whereas the background model was constructed using a total of 37,338 coding-silent mutations.
3.
Application to whole exome sequencing TCGA datasets
We downloaded somatic mutations of four TCGA datasets whose moratorium period has expired: breast invasive carcinoma (BRCA) (Bell et al., 2011) , lung squamous cell carcinoma (LUSC) (Hammerman et al., 2012) , ovarian serous carcinoma (OV) (Bell et al., 2011) and uterine corpus endometrioid carcinoma (UCEC) (Getz et al., 2013) . These datasets possess a large number of silent mutations thus producing a good background model; in addition, MutSig results were available for all of them. They were downloaded from the latest available run at October 2012 at the Broad Institute Firehose system.
We removed from the OncodriveCLUST analysis samples with abnormally high number of mutations in each dataset, i.e., greater than the median of the entire distribution as compared to the remaining samples. These were identified as outliers of the distribution of mutations per sample in each dataset. Overall, 12 such outliers appeared in UCEC but none in the remaining datasets. OncodriveCLUST assessed significant clustering of all genes with protein-affecting mutations in at least 3 samples of each cancer dataset. As stated above, the results of OncodriveCLUST in each TCGA dataset were compared with the ones of a frequency-based analysis (MutSig) and a functional impact bias analysis (OncodriveFM). All the analyses aimed to find driver candidates were performed using the same mutation data. OncodriveFM was run for all genes with protein-affecting mutations in more than 2 samples of the OV and BRCA datasets and in more than 5 samples in UCEC and LUSC. Heatmaps depicted in the present manuscript were constructed using Gitools (Perez-Llamas & Lopez-Bigas, 2011). Venn diagrams were created with the BioVenn application (Hulsen, De Vlieg, & Alkema, 2008) . Meaningful positions are selected as those having a number of mutations that is not expected by chance (filled in orange in the present panel). This is calculated for each gene depending on its length and its number of mutations according to the binomial cumulated distribution function, which is a loose criteria according to our non-uniform distribution of mutations hypothesis (probability < 1% by default to state a position as meaningful). In the present panel, the minimum number of mutations calculated for each gene as the meaningful threshold is represented by the label 'Th' in the lower right part of the panel. (III) Meaningful positions found in step (II) are grouped to form mutation clusters (shadowed in grey in the presented panel). Two consecutive positions are grouped within the same cluster if there is a default maximum distance of 5 amino acids between them. This is considered a stringent cut-off to define that two mutations in different residues are affecting the same tumorigenic mechanism, as stressed by the fact that most (95%) of the coding-silent mutations, which are assumed to be stochastically distributed, of the COSMIC data set are separated by larger distances. Note that if no meaningful position is found across the protein sequence, the gene is considered to have no mutation clusters and therefore no further analysis is performed. In the present example, gene A has a single meaningful position and thus it forms a single cluster; in gene B, there are 6 meaningful positions that are grouped forming two separate clusters. (IV) Mutations that do not occur in the meaningful positions found in (II) but are either enclosed within the boundaries of the clusters defined in (III) or adjacent to them are also accounted for the final figure of the number of mutations enclosed by that cluster (note that new positions filled in orange within each cluster appeared in the present panel). (V) Thereafter, a score is calculated for each cluster. This score is proportional to the number of enclosed mutations and inversely related to the cluster length (see the Methods section for further details about the clustering score calculation). A final value per gene is obtained by summing the scores of each of the clusters found in that gene (C1 for gene A and C1 plus C2 for gene B).
(VI) Finally, to estimate the significance of each gene score obtained in (V), this is compared with the distribution of the background model. The background model is obtained by calculating the clustering scores of all the dataset genes following steps (I-V) but analysing the coding-silent mutations. Note that such comparison allows to obtain a standard score (i.e., a Z score) after the normal distribution of the background model has been validated, and a corrected p value is thereafter derived.
RESULTS
Motivation and hypothesis
Mutation recurrence and the accumulation of functional mutations across samples have both been employed to identify genes with positively selected mutations during tumorigenesis, which are thus good candidates to play an important role in this process. On the other hand, the physical grouping of mutations in certain protein regions -although recognized as a signal of positive selection-has not been exploited as thoroughly for this purpose. For instance, the MuSiC tool which is aimed to identify recurrently mutated genes, also points at genes with a high density of mutations, through the so-called proximity analysis (Dees et al., 2012) , but it does not attempt to estimate the significance of such observation. Other approaches developing an analytical framework, base their calculations on the oversimplified assumption of a homogeneous background distribution of mutations (see below) (Ye et al., 2010) . In this study, we present a novel computational method able to identify genes biased towards a significant clustering of mutations within regions of the protein sequence and we assess its ability to nominate cancer drivers. Our method defines clusters by grouping together mutations that are in physical proximity. Also, based on the acknowledgment that mutations do not occur with equal probability on all positions of a gene, the OncodriveCLUST background model relies on the degree of clustering of silent mutations observed across genes in the dataset under analysis.
Silent mutations do not follow a uniform distribution
Previously described methods to assess the significance of mutation clustering assume that the baseline mutation probability is homogeneous across all gene positions (Stehr et al., 2011; Wagner, 2007; Ye et al., 2010; Yue et al., 2010) , an assumption that seems oversimplified according to recent evidences of non-random mutation processes along the genome (Amos, 2010; Liu, De, & Michor, 2013; Martincorena, Seshasayee, & Luscombe, 2012; Roberts et al., 2012) . As a first step to overcome this problem, our method measures the clustering of coding-silent mutations, which are assumed not to be under selective pressure and may thus reflect the baseline tendency of somatic mutations to preferentially occur at certain positions of the protein sequence.
We collected COSMIC entries annotated as whole genome screens and we constructed the background model using the synonymous mutations found in this dataset. In general, coding-silent mutations did not follow a uniform distribution but were instead noticeably grouped (Supp Figure 2) . Therefore, protein-affecting mutations that are not clustered beyond this point may reflect spurious findings, stressing the benefit of using a nonhomogeneous mutations distribution null model to retrieve more specific results. Interestingly, some of the clustered coding-silent mutations may well represent unknown functional variants positively selected during the tumorigenic process and deserve further study, which is beyond the scope of the present manuscript. In any case, we assume that the vast majority of coding-silent variants are under neutral selection; therefore, we used their general clustering distribution to construct our background model.
3.
Genes with mutation clustering detected by OncodriveCLUST are enriched for known cancer genes Analysis of the COSMIC dataset included 9,565 genes that contained at least 10 protein-affecting mutations annotated as whole genome screen. Of these, 6,024 showed at least one cluster of mutations according to the OncodriveCLUST criteria and were assessed for significance. Overall, 123 genes were biased towards a larger mutation clustering as compared to the aforementioned background model (corrected p value < 5%). The output of this analysis is provided in Supplemental File 1. Genes selected by OncodriveCLUST were enriched for known cancer drivers included in the CGC (27/122 = 22% vs. 232/9444 = 2.4%). Most of these (19/27 = 70%) possessed a dominant phenotype according to the CGC annotation. Nevertheless, we also detected significant clusters among recessive cancer genes, which were wider, as a rule. These results support the hypothesis that clustering is more pronounced among genes that experience gainof-function, although mutations leading to loss-of-function in some genes also occur predominantly within certain regions of the protein (Figure 2) . Next, we used OncodriveCLUST to analyse the four selected TGCA datasets. In all of them, the genes nominated by OncodriveCLUST were enriched for known cancer drivers (Supp Figure 3) . The detailed output of these analyses is provided in Supplemental Files 2-5. The observation that known cancer genes were consistently selected by OncodriveCLUST as bearing significant mutations clusters demonstrate that this method is also useful to nominate novel drivers. 
Using OncodriveCLUST to complement results of other methods to identify drivers
There are crucial cancer genes that cannot be identified by the mutation clustering approach, such as tumour suppressors whose loss-of-function mutations are evenly distributed across the sequence. Moreover, the ability to measure the mutations clustering depends on the number of observed mutations. Therefore, this approach in general is not suitable to detect lowly recurrent drivers. As a consequence, the analysis of somatic mutations in a tumour cohort with OncodriveCLUST may provide a list of reliable but incomplete candidate drivers. The retrieval of a more comprehensive driver list requires the combination of several methods that use complementary criteria to identify genes bearing signals of positive selection. We anticipate that the analysis of mutations clustering may combine well with OncodriveFM, a method based on the accumulation of mutations with high functional impact within genes as a marker of positive selection. Since there are other methods aimed to identify driver mutations, we also compared the Oncodrive results with those obtained by a current well-established approach, MutSig, which is based on analysing whether a gene is mutated more often than expected by chance across a cohort of tumour samples.
As a result of this comparison, we found some genes identified by OncodriveCLUST that were missed by the other methods. Some of these are found in the CGC, and are thus likely drivers identified by clustering criteria but not by functional impact or recurrence analysis; interestingly, most of them (9 out of 11) exhibit a dominant phenotype (Figure 3) . In addition to genes included in the CGC, OncodriveCLUST is also able to highlight novel driver candidates that are overlooked by other methods. For instance, among the 55 genes with significant mutation clusters in the BRCA dataset, 38 were not identified by other methods -as PLA2G3 (involved in cell growth and death), MMP14 (matrix metalloproteinase), REV1 (involved in DNA repair) and the caspase CASP5. These may be regarded as potential candidates to drive the emergence of the tumour phenotype that were selected only by the OncodriveCLUST method (Supp Figure 3) . Figure 3 . Selected top-ranking genes from the OncodriveCLUST analysis on four TCGA datasets. Summary of the results obtained by three methods aimed to find driver genes for the four analysed datasets retrieved from the Cancer Genome Atlas (TCGA) project: OncodriveFM (functional impact criteria), OncodriveCLUST (mutation clustering criteria) and MutSig (mutation frequency criteria). Only genes annotated in the Cancer Gene Census are depicted. Combination of approaches based on different theoretical principles confers different levels of evidence. Note that OncodriveCLUST selected genes likely to be involved in the disease, several of them missed by the other methods. The label 'Not assessable' denotes genes whose functional impact metrics cannot be calculated (OncodriveFM), or genes with no mutation cluster (OncodriveCLUST).
DISCUSSION
The elucidation of cancer drivers relies on identifying the marks of positive selection that occur during the clonal evolution of tumours. The trend shown by protein-affecting mutations to accumulate predominantly in certain gene regions is a fingerprint that may denote events targeted by the tumourigenesis. However, it is now apparent that the probability of occurrence of somatic mutations is affected by several factors and varies across the genomic sequence (Amos, 2010; Liu et al., 2013; Martincorena et al., 2012; Roberts et al., 2012) . This should be taken into account when identifying mutation clusters, since the assumption of a uniform mutation distribution as the null model may overestimate the significance of observed clusters.
However, the factors determining the occurrence of mutational hotspots are not fully understood, and their inference is not straightforward by mining the data under analysis to obtain a background model per gene and sample. Instead, we propose to construct the background model using the degree of clustering of synonymous mutations, which are assumed not to be under positive selection and may thus reflect the baseline mutation clustering of the tumour. This assumption also probably comprises a simplification, since some coding-silent mutations could in principle alter processes such as chromatin remodeling or mRNA processing. Nevertheless, apart from this, they are not in general functionally involved in tumorigenesis. Moreover, and due to the low-recurrence of synonymous mutations, the background model cannot establish constraints for particular genomic regions. Therefore, the method presents several caveats which have to be taken into account. However, although limited, this null model shall in principle specifically support the identification of genes whose mutations are grouped above the background. As a matter of fact, this approach was proven successful in prioritizing genes involved in the disease, since OncodriveCLUST retrieved a reduced list of genes enriched for cancer drivers in all the datasets analysed. In general, the clustering analysis better detected drivers known to exhibit a dominant phenotype, since mutations in these genes occur at particular sites that lead to the favoured gain-offunction. However, recessive genes were also highlighted over the background model, since their mutations occur in larger but still delimited regions leading to loss-of-function.
The identification of drivers can profit from the combination of methods based on different theoretical principles, in particular if they use complementary criteria. In this regard, OncodriveCLUST complements OncodriveFM because it better captures the behaviour of gain-of-function cancer genes whereas OncodriveFM is better at identifying tumour suppressor genes, which bear loss-of-function mutations that usually receive higher functional impact scores. By comparison, mutations conferring gain-of-function are more prone to produce lower scores of functional impact. For instance, mutations that change residue 1047 of PIK3CA are known to be oncogenic but are underestimated by functional impact metrics, since they rely largely on conservation criteria and this particular residue is highly variable across species. Therefore, OncodriveFM overlooks this gene in the BRCA dataset because most PIK3CA mutations occur in that specific position. Nevertheless, this scenario in which gene mutations predominantly occur at certain protein positions is well highlighted by the OncodriveCLUST analysis, illustrating how the bias of a method is captured by using complementary criteria.
At present, the most widely-used approach to identify driver genes consists in detecting those that are mutated more frequently than expected by chance. Therefore, we compared the OncodriveCLUST results obtained in the TGCA datasets to those obtained by MutSig (Getz et al., 2007) , a well-established method to detect significantly mutated genes across cohorts of tumour samples. To avoid further interpretation, we limited the comparison to already well described drivers, i.e., genes contained in the CGC. As a result, we demonstrated that OncodriveCLUST selected several cancer drivers that were missed not only by OncodriveFM but also by the recurrence analysis. Of note, this suggests that OncodriveCLUST could identify novel driver candidates (i.e., not included in the CGC) that are nevertheless overlooked by other methods and emphasizes the benefit of using a combination of methods to elucidate driver genes that balances the strengths and weaknesses of each approach. This would allow the retrieval of a more comprehensive list of putative drivers, since each may exhibit different signals of positive selection. In addition, it could also help to estimate the reliability of the results, since the false positives of a method are unlikely to be picked up by another one based on complementary criteria and therefore with its own sources of bias.
One important advantage of OncodriveCLUST, and of OncodriveFM as well, is that the required input consists only on the list of tumour somatic mutations in the cohort. Raw data, such as BAM files are not required, which reduces the burden of download, storage and computational processing. This is a major issue, since the amount of data generated by tumour genome resequencing studies continues to increase and the technical requirements of some methods could limit the analysis of large datasets. This is specially true for initiatives aimed at integrating data from different projects (e.g. IntOGen (Gundem et al., 2010) ).
In summary, the elucidation of genes involved in cancer is a challenging task that requires the combined use of approaches based on different criteria. In this regard, we show that OncodriveCLUST complements well other existing methods and should be taken into account for the identification of cancer drivers.
